Why is $CYTK moving today? · SEC 8-K archive

$CYTK SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $CYTK: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $CYTK filing catalyst

Why did $CYTK trigger an AI stock catalyst alert?

$CYTK triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.5/10). Headline: Cytokinetics Reports Q3 2026: Total Revenue $47.6M Led by $44.5M Aficamten Sales. Key points: - Total Q3 revenues grew to $47.6M vs $1.9M YoY, driven by $44.5M in MYQORZO (aficamten) net product revenue. - Operating loss remained flat YoY at -$167.1M due to commercialization and R&D expenses. - Strong balance sheet with ~$1.6B in cash, equivalents, and investments as of Sept 30, 2026.

How did $CYTK stock react after the SEC filing?

After the SEC 8-K for $CYTK, observed market reaction: T0 price $63.60. Past moves do not guarantee future results.

Where can I get real-time $CYTK SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $CYTK via Telegram and the VIP Web Terminal from €10/month.

$CYTK

$CYTK – Cytokinetics Reports Q3 2026: Total Revenue $47.6M Led by $44.5M Aficamten Sales

CYTOKINETICS INC

2026-11-04 00:00:00 UTC · SEC 8-K · All $CYTK

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.5 / 10)

Total Q3 revenues grew to $47.6M vs $1.9M YoY, driven by $44.5M in MYQORZO (aficamten) net product revenue.
Operating loss remained flat YoY at -$167.1M due to commercialization and R&D expenses.
Strong balance sheet with ~$1.6B in cash, equivalents, and investments as of Sept 30, 2026.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →